NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
19.02
+0.37 (1.98%)
Jul 26, 2024, 4:00 PM EDT - Market closed
NovoCure Employees
NovoCure had 1,453 employees as of December 31, 2023. The number of employees increased by 133 or 10.08% compared to the previous year.
Employees
1,453
Change (1Y)
133
Growth (1Y)
10.08%
Revenue / Employee
$378,502
Profits / Employee
-$116,104
Market Cap
2.05B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,453 | 133 | 10.08% |
Dec 31, 2022 | 1,320 | 153 | 13.11% |
Dec 31, 2021 | 1,167 | 144 | 14.08% |
Dec 31, 2020 | 1,023 | 241 | 30.82% |
Dec 31, 2019 | 782 | 184 | 30.77% |
Dec 31, 2018 | 598 | 103 | 20.81% |
Dec 31, 2017 | 495 | 35 | 7.61% |
Dec 31, 2016 | 460 | 142 | 44.65% |
Dec 31, 2015 | 318 | 60 | 23.26% |
Dec 31, 2014 | 258 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
BrightSpring Health Services | 35,000 |
National HealthCare | 13,123 |
Amphastar Pharmaceuticals | 1,761 |
STAAR Surgical Company | 1,115 |
LeMaitre Vascular | 630 |
Recursion Pharmaceuticals | 500 |
Immunocore Holdings | 497 |
Syndax Pharmaceuticals | 184 |
NVCR News
- 1 day ago - Novocure Reports Second Quarter 2024 Financial Results - Business Wire
- 25 days ago - Novocure to Report Second Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival - Business Wire
- 2 months ago - TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany - Business Wire
- 3 months ago - Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon - Business Wire
- 3 months ago - Novocure Reports First Quarter 2024 Financial Results - Business Wire
- 3 months ago - Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 - Business Wire
- 4 months ago - Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 - Business Wire